Allan Andrews, MD
Gastroenterology · Supply, NCNPI 1225199409
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 73 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Pfizer at 27.0% of the total. Reporting peaked in 2019 at $441 and has fallen 87.1% since, to $57 in 2025. That places this record below the midpoint for gastroenterology clinicians in NC, where the typical reported total is $1,694.
Across 73 payments — averaging $14.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$294
- AbbVie$190
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$188
- Amgen$81
- Gilead$80
- Intercept Pharmaceuticals, Inc.$44
- plus $213 from 10 others
Across 65 payments — averaging $4599.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$133K
- Ironwood Pharmaceuticals, Inc$130K
- AbbVie$36K
What the payments were for
- Consulting fees$141%
- Food & beverage$1,07799%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 26 | $294 |
| AbbVie | 10 | $190 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $188 |
| Amgen | 4 | $81 |
| Gilead | 5 | $80 |
| Intercept Pharmaceuticals, Inc. | 3 | $44 |
| Johnson & Johnson | 2 | $35 |
| Dynavax Technologies Corporation | 2 | $34 |
| Merck | 2 | $31 |
| Radius Health, Inc. | 2 | $26 |
| Boston Scientific | 1 | $18 |
| Braintree Laboratories, Inc. | 1 | $16 |
| Dova Pharmaceuticals | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
| Biodelivery Sciences International, Inc. | 1 | $11 |
How this compares
$1,091 in reported general payments places this provider in the 40th percentile of 610 gastroenterology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 12 | $81,693 |
| XifaxanRifaximin | 28 | $81,587 |
| Cimzia (2 Pack)Certolizumab Pegol | 13 | $65,755 |
| LinzessLinaclotide | 21 | $17,988 |
| Mesalamine | 23 | $17,165 |
| Dicyclomine Hcl | 356 | $6,390 |
| Pantoprazole Sodium | 323 | $4,380 |
| Omeprazole | 298 | $4,253 |
| Ursodiol | 12 | $3,984 |
| Esomeprazole Magnesium | 34 | $3,525 |
| Amitriptyline Hcl | 76 | $1,125 |
| CholestyramineCholestyramine (With Sugar) | 18 | $967 |
| Azathioprine | 12 | $371 |
| Furosemide | 23 | $73 |
| Prednisone | 14 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $188 | $81,58728 claims |
| AbbVieLinzess | $190 | $17,98821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 610 gastroenterology providers in North Carolina.
Other gastroenterology in Supply
- Stephen DealCharlotte$945K
- Fred FowlerCharlotte$932K
- Paul WatkinsChapel Hill$876K
- Nilesh LodhiaCharlotte$735K
- Evan DellonChapel Hill$431K
- Robert ReindollarSalisbury$430K
- Andrew StormWinston Salem$426K
- John PoulosFayetteville$407K
- Manal AbdelmalekDurham$402K
- Christopher McGowanCary$223K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.